18F-Floretyrosine Expanded Access Program

NCT06743100 | Unknown

• 1 other identifier: 18F-TLX101-CDX-002
• Study Type: expanded_access
• Target: N/A
• Locations: 1 country
• Sites: 7

Brief Summary

The aim of this Expanded Access Program (EAP) is to enable the use of 18F-Floretyrosine with positron emission tomography/computed tomography (PET/CT) or positron emission tomography/magnetic resonance (PET/MR) imaging to noninvasively detect tumor burden or treatment related change to assist in optimal management of patients with glioma.

Conditions

Glioma (Any Grade) in the Brain

Interventions

18F-Floretyrosine DIAGNOSTIC_TEST

Single IV administration on Day 0, followed by a PET/CT or PET/MR diagnostic scan 20-40 minutes after the IV administration of 18F-Floretyrosine.

Eligibility Criteria

• Age: 3 Years+
• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Written and voluntarily given informed consent. Pediatric patients (\<18 years of age) will provide assent along with parental/legal guardian /caregiver consent according to IRB requirements.
• Male or female ≥ 3 years of age at time of consent/assent
• Diagnosis or clinical suspicion of glioma (any grade) in the brain
• At the time of screening have undergone therapy for glioma
• Indeterminate MR findings for disease recurrence or progression versus treatment related changes (pseudoprogression or pseudoresponse) requiring further diagnostic procedures within 60 days prior to the 18F-Floretyrosine PET imaging
• Willing and able to lie still for at least 40 minutes in an enclosed space for the imaging procedure, or if medically necessary, able to tolerate standard institutions procedures for sedation and/or anesthesia.

You may not qualify if:

• Participant cannot be safely scanned due to devices, implants, foreign and/or metallic objects in or on the body that are not MR compatible, unless a clinical judgement is made that the participant's diagnostic needs can instead be met by diversion to 18F-Floretyrosine imaging by PET/CT (making the magnetic field compatibility an irrelevant safety concern).
• Women who are pregnant or breastfeeding.
• Women of childbearing potential who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for the duration of the program (Day 0 to Day 2).
• Serious non-malignant disease (e.g., psychiatric, infectious, autoimmune, or metabolic), that may interfere with the objectives of the program or with the safety or compliance of the participant, as judged by the Investigator.
• Mental impairment that may compromise the ability to give informed consent/assent and comply with the requirements of the program as judged by the Investigator.
• Exposure to any experimental diagnostic or therapeutic drug within 30 days from the date planned administration of 18F-Floretyrosine.
• Known hypersensitivity to floretyrosine or tyrosine derivatives.
• Unable to tolerate the program procedures.

Sponsors & Collaborators

• Telix Pharmaceuticals (Innovations) Pty Limited: lead

Study Sites (7)

CU Anschutz / University of Colorado

Aurora, Colorado, 80045, United States

AVAILABLE

Northwestern University

Chicago, Illinois, 60611, United States

AVAILABLE

Johns Hopkins Baltimore

Baltimore, Maryland, 21205, United States

AVAILABLE

Kettering Health Main Campus

Kettering, Ohio, 45429, United States

AVAILABLE

University Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

AVAILABLE

Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States

AVAILABLE

University Wisconsin Madison

Madison, Wisconsin, 53705-2275, United States

AVAILABLE

MeSH Terms

Conditions

Glioma

Condition Hierarchy (Ancestors)

Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Central Study Contacts

Study Project Manager

CONTACT

(317)588-9700; eap-americas@telixpharma.com

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 16, 2024
• First Posted: December 19, 2024
• Last Updated: April 2, 2025

Record last verified: 2025-03

Locations

US (7)